Discovery of a dual CCR2/CCR5 antagonist with a superior cardiovascular profile for the treatment of autoimmune diseases

被引：0
|
作者：
Hughes, Robert O. [1 ]
Rogier, D. Joseph [1 ]
Devraj, Rajesh [1 ]
Xue, Chu-Biao [2 ]
Cao, Ganfeng [2 ]
Turner, Steven R. [1 ]
Morton, Philip A. [1 ]
Keys, Kelly [1 ]
Covington, Maryanne [2 ]
Bond, Brian R. [1 ]
Yu, Ying [1 ]
Meade, Holly [1 ]
Hood, William F. [1 ]
Roeberds, Steve [1 ]
Newton, Robert [2 ]
Metcalf, Brian [2 ]
机构：
[1] Pfizer Res & Dev, Cambridge, MA 02451 USA
[2] Incyte Corp, Willmington, DE 19880 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2011年 / 242卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
26-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1-Infected, Treatment-Experienced, CCR5 Antagonist-Naive Subjects
    Lalezari, Jacob
    Gathe, Joseph
    Brinson, Cynthia
    Thompson, Melanie
    Cohen, Calvin
    Dejesus, Edwin
    Galindez, Jorge
    Ernst, Jerome A.
    Martin, David E.
    Palleja, Sandra M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 57 (02) : 118 - 125
  • [22] Concerted evolution of vertebrate CCR2 and CCR5 genes and the origin of a recombinant equine CCR5/2 gene
    Perelygin, Andrey A.
    Zharkikh, Andrey A.
    Astakhova, Natalia M.
    Lear, Teri L.
    Brinton, Margo A.
    JOURNAL OF HEREDITY, 2008, 99 (05) : 500 - 511
  • [23] Combination therapy with a dual CCR2/CCR5 antagonist and a FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis
    Puengel, Tobias
    Lefere, Sander
    Hundertmark, Jana
    Penners, Christian
    Van de Velde, Frederique
    Lapauw, Bruno
    Devisscher, Lindsey
    Geerts, Anja
    Boehm, Stephanie
    Zhao Qihong
    Krupinski, John
    Charles, Edgar
    Zinker, Bradley
    Tacke, Frank
    JOURNAL OF HEPATOLOGY, 2020, 73 : S13 - S13
  • [24] The dual CCR2/CCR5 inhibitor Cenicriviroc ameliorates murine primary biliary cholangitis
    Reuveni, D.
    Leung, P.
    Vig, P.
    Shibolet, O.
    Gershwin, E. M.
    Zigmond, E.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S75 - S76
  • [25] Elucidation of Binding Sites of Dual Antagonists in the Human Chemokine Receptors CCR2 and CCR5
    Hall, Spencer E.
    Mao, Allen
    Nicolaidou, Vicky
    Finelli, Mattea
    Wise, Emma L.
    Nedjai, Belinda
    Kanjanapangka, Julie
    Harirchian, Paymann
    Chen, Deborah
    Selchau, Victor
    Ribeiro, Sofia
    Schyler, Sabine
    Pease, James E.
    Horuk, Richard
    Vaidehi, Nagarajan
    MOLECULAR PHARMACOLOGY, 2009, 75 (06) : 1325 - 1336
  • [26] CENICRIVIROC MESILATE Chemokine CCR2/CCR5 Receptor Antagonist Anti-HIV Agent
    Reviriego, C.
    DRUGS OF THE FUTURE, 2011, 36 (07) : 511 - 517
  • [27] Dual CCR2/CCR5 antagonism as macrophage targeted therapy in experimental hepatocellular carcinoma
    Degroote, Helena
    Vandierendonck, Astrid
    Xavier, Verhelst
    Anja, Geerts
    Hans, Van Vlierberghe
    Devisscher, Lindsey
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E359 - E359
  • [28] Cenicriviroc, a CCR2/CCR5 antagonist, promotes the generation of type 1 regulatory T cells
    Madan, Upasna
    Verma, Bhawna
    Awasthi, Amit
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 (07)
  • [29] CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse
    Solomon, Michelle
    Balasa, Balaji
    Sarvetnick, Nora
    AUTOIMMUNITY, 2010, 43 (02) : 156 - 163
  • [30] CCR2 and CCR5 gene polymorphisms and susceptibility to sarcoidosis.
    Wischmeijer, TA
    Bombieri, C
    Agostini, C
    Semenzato, GP
    Luisetti, M
    Pignatti, PF
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (04) : 485 - 485
12345